Provided by Tiger Trade Technology Pte. Ltd.

Y-mAbs Therapeutics, Inc.

8.61
0.0000
Volume:- -
Turnover:6.54M
Market Cap:391.22M
PE:-17.40
High:8.61
Open:8.61
Low:8.61
Close:8.61
52wk High:16.11
52wk Low:3.55
Shares:45.44M
Float Shares:18.59M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4948
EPS(LYR):-0.6692
ROE:-24.31%
ROA:-8.67%
PB:4.47
PE(LYR):-12.87

Loading ...

HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%

Reuters
·
Oct 01, 2025

Y-mAbs Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08, 2025

Y-mAbs Therapeutics' Q2 revenue falls 14%

Reuters
·
Aug 08, 2025

Y-mAbs Therapeutics Q2 EPS $(0.07) Beats $(0.26) Estimate, Sales $19.52M Beat $18.39M Estimate

Benzinga
·
Aug 08, 2025

Y-mAbs Therapeutics Q2 EPS USD -0.07 VS. Ibes Estimate USD -0.27

THOMSON REUTERS
·
Aug 08, 2025

Y-mAbs Therapeutics Inc : Morgan Stanley Raises to Equal-Weight From Underweight; Raises Target Price to $8.6 From $7

THOMSON REUTERS
·
Aug 06, 2025

Y-mAbs Therapeutics Inc. to Be Delisted from Nasdaq Following Acquisition by SERB Pharmaceuticals

Reuters
·
Aug 06, 2025

Top Midday Gainers

MT Newswires Live
·
Aug 06, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Axon, Cummins, Pfizer

Reuters
·
Aug 06, 2025

JonesTrading Downgrades Y-mAbs Therapeutics to Hold From Buy

MT Newswires Live
·
Aug 06, 2025

Dow Surges Over 100 Points; Pfizer Earnings Top Views

Benzinga
·
Aug 05, 2025

Serb Pharmaceuticals Agrees To Acquire Y-Mabs Therapeutics

Reuters
·
Aug 05, 2025

Y-mAbs Therapeutics Inc - Serb Offers $8.60 per Share for Y-mAbs, 105% Premium

THOMSON REUTERS
·
Aug 05, 2025

Y-mAbs Therapeutics Inc: Serb to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 per Share

THOMSON REUTERS
·
Aug 05, 2025

Y-mAbs Therapeutics Inc. Unveils Presentation on Innovative Oncology Leadership and Therapeutic Platforms

Reuters
·
Jul 25, 2025

Y-mAbs Therapeutics Inc. Held Annual Stockholders Meeting

Reuters
·
Jul 16, 2025

Y-mAbs Therapeutics Inc. Unveils Radiopharmaceutical R&D Update, Showcasing Innovative Approaches to Enhance Patient Safety and Treatment Efficacy

Reuters
·
May 29, 2025

Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating

MT Newswires Live
·
May 28, 2025

Y-mAbs Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 19, 2025

Y-mAbs Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
May 15, 2025